Bandhan Mutual FundEquity Schemes - Sectoral Fund0.9 years
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Too thin to judge
History is short. Lean on older peers or a low-cost index until more evidence lands.
In three lines
Watch if · History is short. Lean on older peers or a low-cost index until more evidence lands.
Prefer peers if · Compare BANDHAN FINANCIAL SERVICES FUND - it has enough history to inspect beside this fund.
Buy checklist
History depth
Fail
0.9 years - thin for judging consistency.
Engine status
n/a
History is short. Lean on older peers or a low-cost index until more evidence lands.
Expense ratio
Pass
1.25% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -10.1%. Ask whether you can hold through a similar fall.
Vs category
n/a
Category relative read still thin.
Manager tenure
Watch
Brijesh Shah · 1.0 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 54.3% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 10%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
If you start a SIP here, diary a 90-day check and an annual review - don’t react to every NAV print.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
31 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-10.1%
7 Jan 2026 – 4 May 2026
Trough 29 Jan 2026 · recovered in 95 days
-8.7%
21 May 2026 – 19 Jun 2026
Trough 2 Jun 2026 · recovered in 17 days
-3.4%
4 Dec 2025 – 7 Jan 2026
Trough 30 Dec 2025 · recovered in 8 days
-2.5%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
n/a
Vs category
n/a
Consistency
n/a
Risk-adjusted
45
Drawdown
75
Mean
n/a
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Too thin to judge
History is short. Lean on older peers or a low-cost index until more evidence lands.
Why this status
No status reasons yet. History is still thin.
Supporting reads
No supporting reads in the current evidence set.
30 Sept 2026 · 37 holdings · top 10 are 54.3%.
Sun Pharmaceutical Industries Ltd
Healthcare
9.7%
Reverse Repo
Unspecified
6.7%
Cipla Ltd
Healthcare
6.2%
Apollo Hospitals Enterprise Ltd
Healthcare
5.8%
Max Healthcare Institute Ltd
Healthcare
5.3%
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Bandhan Mutual Fund
Caveat: Higher volatility · Deeper drawdown
Bandhan Mutual Fund
Caveat: Higher volatility · Deeper drawdown
Bandhan Mutual Fund
Caveat: Higher volatility · Deeper drawdown
DSP Mutual Fund
Caveat: Higher volatility · Deeper drawdown
DSP Mutual Fund
Caveat: Higher volatility · Deeper drawdown
Bandhan Mutual FundEquity Schemes - Sectoral Fund0.9 years
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Too thin to judge
History is short. Lean on older peers or a low-cost index until more evidence lands.
In three lines
Watch if · History is short. Lean on older peers or a low-cost index until more evidence lands.
Prefer peers if · Compare BANDHAN FINANCIAL SERVICES FUND - it has enough history to inspect beside this fund.
Buy checklist
History depth
Fail
0.9 years - thin for judging consistency.
Engine status
n/a
History is short. Lean on older peers or a low-cost index until more evidence lands.
Expense ratio
Pass
1.25% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -10.1%. Ask whether you can hold through a similar fall.
Vs category
n/a
Category relative read still thin.
Manager tenure
Watch
Brijesh Shah · 1.0 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 54.3% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 10%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
If you start a SIP here, diary a 90-day check and an annual review - don’t react to every NAV print.
NAV
29 Oct 2026 · +9.6% over 1Y
10.915
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
29 Oct 2026
-5.7%
31 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-10.1%
7 Jan 2026 – 4 May 2026
Trough 29 Jan 2026 · recovered in 95 days
-8.7%
21 May 2026 – 19 Jun 2026
Trough 2 Jun 2026 · recovered in 17 days
-3.4%
4 Dec 2025 – 7 Jan 2026
Trough 30 Dec 2025 · recovered in 8 days
-2.5%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
n/a
Vs category
n/a
Consistency
n/a
Risk-adjusted
45
Drawdown
75
Mean
n/a
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Too thin to judge
History is short. Lean on older peers or a low-cost index until more evidence lands.
Why this status
No status reasons yet. History is still thin.
Supporting reads
No supporting reads in the current evidence set.
30 Sept 2026 · 37 holdings · top 10 are 54.3%.
Sun Pharmaceutical Industries Ltd
Healthcare
9.7%
Reverse Repo
Unspecified
6.7%
Cipla Ltd
Healthcare
6.2%
Apollo Hospitals Enterprise Ltd
Healthcare
5.8%
Max Healthcare Institute Ltd
Healthcare
5.3%